Showing results (21-30 of 152) with videos related to
Sort By:
Pageof 16
The Prostate|June 11, 2005
Lymphatic vessel density and lymph node metastasis in prostate cancerYiping Zeng, Kenneth Opeskin, Lisa G Horvath, et al.Journal of Bone Oncology|February 25, 2016
The role of the bone microenvironment in skeletal metastasisYu Zheng, Hong Zhou, Colin R Dunstan, et al.Molecular Cancer Therapeutics|October 5, 2007
Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolismCaroline G Roberts, Ebru Gurisik, Trevor J Biden, et al.Human Genetics|April 26, 2011
Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypesMarina Pajic, Christopher J Scarlett, David K Chang, et al.Breast Cancer Research and Treatment|May 21, 2003
Cyclin D1, EMS1 and 11q13 amplification in breast cancerChristopher J Ormandy, Elizabeth A Musgrove, Rina Hui, et al.International Journal of Cancer|July 17, 2003
Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progressionSophie F Doisneau-Sixou, Philippe Cestac, Jean-Charles Faye, et al.Cancer Research|April 17, 2008
The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell aciniC Elizabeth Caldon, Alexander Swarbrick, Christine S L Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancerAnish Bali, Philippa M O'Brien, Lyndal S Edwards, et al.Advances in Experimental Medicine and Biology|July 22, 2008
Cell cycle machinery: links with genesis and treatment of breast cancerAlison J Butt, C Elizabeth Caldon, Catriona M McNeil, et al.Cancer Research|October 3, 2007
Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinibPaul Timpson, Ashleigh S Wilson, Gillian M Lehrbach, et al.Pageof 16